IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)            

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A Critical Review: Blood and Clinical Hematology Disorders in Covid-19

Author: MUHAMMAD DARWIN PRENGGONO, MOHAMMAD RUDIANSYAH, NUVITA HASRIANTI
Abstract: Severe acute respiratory coronavirus 2 (SARS–CoV– 2) is a pathogen virus from the infectious Coronavirus disease which was reported first in Wuhan, Hubei Province, by the People’s Republic of China to WHO on December 31st, 2019. Due to its rapid and global spread that infected about 2 million people with mortality rate of more than 150.000, it was declared a pandemic on March 12th, 2020. The opening speech of the WHO Director General on the media about COVID-19 was carried out on March 18th, 2020, and it was stated that the virus needs rapid and large scale tests. Therefore, Solidarity Test was chosen because it may help reduce 80% of the time that is needed in a research rather than random clinical check that requires longer time. Based on the data from several countries, it was found that COVID-19 is a systemic infection disease that brings significant effect to hematopoietic systems and hemostasis such as low ALC and high LDH which was found in many ICU patients. Lymphopenia is considered to be a cardinal laboratory finding with potentials of being a prognosis. Blood disorders in COVID-19 are divided are divided into two, namely malignant and nonmalignant. However, this study mainly focused on non-malignant blood disorders.
Keyword: COVID-19, blood disorders, coagulopathy, laboratory, therapy
DOI: https://doi.org/10.31838/ijpr/2021.13.02.079
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free